Drug class
Isoniazids
The term "Isoniazids" is not a formal standalone therapeutic drug class in standard regulatory classifications such as the FDA Established Pharmacologic Class (EPC) system, but rather refers to the specific antimycobacterial agent isoniazid (isonicotinic acid hydrazide) and its related hydrazide chemical analogues. Read more about Isoniazids
12 drugs in this class 11 manufacturers
Drugs in Isoniazids
The term "Isoniazids" is not a formal standalone therapeutic drug class in standard regulatory classifications such as the FDA Established Pharmacologic Class (EPC) system, but rather refers to the specific antimycobacterial agent isoniazid (isonicotinic acid hydrazide) and its related hydrazide chemical analogues.
Functioning as a prodrug activated by the bacterial enzyme KatG, isoniazid exerts potent bactericidal activity by inhibiting the enoyl-ACP reductase InhA, thereby disrupting mycolic acid synthesis essential for the mycobacterial cell wall.
Within professional therapeutics, it serves as a foundational first-line antimycobacterial agent primarily indicated for both the prevention of latent infection and the multi-drug treatment of active disease caused by *Mycobacterium tuberculosis*.
-
fda.gov
The term "Isoniazids" is not a formal standalone therapeutic drug class in standard regulatory classifications such as the FDA Established Pharmacologic Class (EPC) system, but rather refers to the specific antimycobacterial agent isoniazid (isonicotinic acid hydrazide) and its related hydrazide chemical analogues
-
nih.gov
The term "Isoniazids" is not a formal standalone therapeutic drug class in standard regulatory classifications such as the FDA Established Pharmacologic Class (EPC) system, but rather refers to the specific antimycobacterial agent isoniazid (isonicotinic acid hydrazide) and its related hydrazide chemical analogues
-
nih.gov
Within professional therapeutics, it serves as a foundational first-line antimycobacterial agent primarily indicated for both the prevention of latent infection and the multi-drug treatment of active disease caused by *Mycobacterium tuberculosis*
-
pharmacompass.com
Within professional therapeutics, it serves as a foundational first-line antimycobacterial agent primarily indicated for both the prevention of latent infection and the multi-drug treatment of active disease caused by *Mycobacterium tuberculosis*
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.